Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting
October 18 2019 - 7:30AM
Business Wire
Cerus Corporation (Nasdaq:CERS) announced today its schedule of
key events and presentations at the 2019 AABB Annual Meeting which
is taking place in San Antonio, Texas on October 19th through
October 22nd.
The AABB Annual Meeting is one of the largest scientific
symposiums focused on the field on transfusion medicine. Scientists
and clinicians from around the globe will be attending to learn
about the latest developments in the industry, including the
recently published final FDA guidance document on mitigating the
risk of bacterial contamination in transfused platelet
components.
“We are looking forward to the AABB meeting and sharing with the
transfusion medicine community the latest clinical data supporting
the use of INTERCEPT treated blood components. Between Cerus and
our scientific collaborators, we will have 23 abstracts, including
6 oral presentations related to INTERCEPT,” said Dr. Richard
Benjamin, Cerus’ Chief Medical Officer.
“We think the Swiss experience supporting the use of INTERCEPT
treated platelets with a 7-day shelf-life in routine use in
allogeneic stem cell transplant recipients over more than 5 years
and data showing the absence of septic transfusions with
pathogen-reduced platelets compared to culture-screened platelets
that used a secondary rapid test on day 5 will be of particular
interest at the conference given the final FDA guidance document,”
continued Benjamin.
Company representatives from Cerus will be in the exhibition
area at both #1133.
A full list of Cerus related abstracts can be viewed at
https://intercept-usa.com/aabb2019. Information on Cerus’ industry
workshop can be viewed at
https://intercept-usa.com/images/AABB2019/Cerus_AABB_Workshop_Postcard__email.pdf.
Schedule of select oral presentations of interest and Cerus’
industry workshop (listed chronologically, all times in Central
Daylight Time)
All meeting rooms are located in the Henry B. Gonzalez
Convention Center.
Sunday, October 20, 2019
7:00 – 8:15 am - Cerus Corporation Industry Workshop: Are you
ready for FDA’s Bacterial Contamination Guidance?, Room 214AB
4:45 - 5:00 pm - OA4-SN5-37: Pathogen Reduced Platelets Reduce
Septic Transfusion Reactions Compared to Conventional Platelets –
Despite Point of Release Testing, Room 302
Tuesday, October 22, 2019
11:30 – 11:45 am - OA3-TU3-25: Achieving 100% Pathogen Reduced
Platelet Component Inventory with Production Optimization and
Variable Dosing, Room 301
11:45 – 12:00 pm - OA4-TU3-25: Five Years of Routine Experience
Using Amotosalen/UVA-Treated Platelets with Storage up to 7 Days,
Room 301
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System, and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191018005108/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024